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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is supposed to be classified on the basis of post-
bronchodilator lung function. Most longitudinal studies of COPD, though, do not have post-bronchodilator lung
function available. We used pre-and post bronchodilator lung function data from the Lung Health Study to
determine whether these measures differ in their ability to predict mortality.
Methods: We limited our analysis to subjects who were of black or white race, on whom we had complete data,
and who participated at either the 1 year or the 5 year follow-up visit. We classified subjects based on their
baseline lung function, according to COPD Classification criteria using both pre- and post-bronchodilator lung
function. We conducted a survival analysis and logistic regression predicting death and controlling for age, sex,
race, treatment group, smoking status, and measures of lung function (either pre- or post-bronchodilator. We
calculated hazard ratios (HR) with 95% confidence intervals (CI) and also calculated area under the curve for the
logistic regression models.
Results: By year 15 of the study, 721 of the original 5,887 study subjects had died. In the year 1 sample survival
models, a higher FEV1 % predicted lower mortality in both the pre-bronchodilator (HR 0.87, 95% CI 0.81, 0.94 per
10% increase) and post-bronchodilator (HR 0.84, 95% CI 0.77, 0.90) models. The area under the curve for the
respective models was 69.2% and 69.4%. Similarly, using categories, when compared to people with “normal” lung
function, subjects with Stage 3 or 4 disease had similar mortality in both the pre- (HR 1.51, 95% CI 0.75, 3.03) and
post-bronchodilator (HR 1.45, 95% CI 0.41, 5.15) models. In the year 5 sample, when a larger proportion of subjects
had Stage 3 or 4 disease (6.4% in the pre-bronchodilator group), mortality was significantly increased in both the
pre- (HR 2.68, 95% CI 1.51, 4.75) and post-bronchodilator (HR 2.46, 95% CI 1.63, 3.73) models.
Conclusions: Both pre- and post-bronchodilator lung function predicted mortality in this analysis with a similar
degree of accuracy. Post-bronchodilator lung function may not be needed in population studies that predict long-
term outcomes.
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Background
COPD is a chronic disease of the lungs and is character-
ized by irreversible airflow limitation, and is currently
the third leading cause of death in the United States
[1-3]. GOLD defines COPD as a preventable and treata-
ble disease with airflow limitation that is usually pro-
gressive and associated with an abnormal inflammatory
response of the lung to noxious particles or gases [4].
Both the American Thoracic Society (ATS) and the
European Respiratory Society (ERS) have, in large part,
adopted this definition [5].
Response to a bronchodilator is thought to be impor-
tant in COPD diagnosis and guidelines suggest that clas-
sification of COPD be made using spirometry performed
after bronchodilator administration [4]. While asthma
generally has more reversibility to a bronchodilator than
COPD, the presence of reversibility does not distinguish
asthma from COPD [6].
According to the 2008 GOLD guidelines “Spirometry
should be performed after the administration of an ade-
quate dose of an inhaled bronchodilator (e.g., 400 μg
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random population study to determine spirometry refer-
ence values, post-bronchodilator values differed from
pre-bronchodilator values [8]. Furthermore, post-
bronchodilator lung function testing in a community
setting has been demonstrated to be an effective method
to identify individuals with COPD [9,10]. However, most
longitudinal studies looking at the effect of impaired
lung function on outcomes such as mortality and hospi-
talizations have used pre-bronchodilator lung function
[11-14].
The purpose of this study is to determine whether
pre- or post-bronchodilator lung function differentially
predict mortality in cohorts over time. Data from the
Lung Health Study [15] was used in this analysis.
Methods
The Lung Health Study (LHS) was a randomized multi-
center clinical trial that was carried out from October
1986 through April 1994 [15,16]. A detailed description
of the LHS design has been previously published [16].
Briefly, “healthy” current smokers between the ages of 35
and 60 were enrolled if their forced expiratory volume in
one second (FEV1) to forced vital capacity (FVC) was less
than 70% and their FEV1 was between 55% and 90% of
the predicted normal value. Subjects were randomized
into three groups: a control group receiving “usual care”,
a smoking intervention group receiving placebo, and a
smoking intervention group receiving the bronchodilator
ipratroprium. Lung function was measured before and
after two inhalations (200-μg total dose) of isoproteronol
from a metered-dose inhaler.
We used data from the year 1(one year following
baseline) and year 5 (5 years following baseline) visits
and included subjects who had complete data and both
pre- and post-bronchodilator lung function measure-
ments at these visits. The rationale for using these visits
was that the inclusion criteria limited the range of lung
disease severity at baseline to mild and moderate
COPD, whereas a broader range could be seen in subse-
quent visits. In addition, prior work has demonstrated
that bronchodilator responsiveness was larger in year 1
and subsequent years than it was at baseline [17].
About 75% of the original cohort of 5887 participants
were followed continuously for 10 years beyond the 5-
year time frame of Lung Health Study I (these subjects
were mostly participants in Lung Health Study III) by
biannual phone contacts (to ascertain vital status, smok-
ing status, morbidity and mortality). Our primary end-
point was all-cause mortality at up to 14.5 years of
follow-up from baseline [18]. The time metric used was
time from the year 1 examination to the time of death
or the end of the study or from the year 5 examination
to the end of the study.
Study Measures
Predicted values from the Third National Health and
Nutrition Examination Survey (NHANES III) were used
in the analysis [19]. We used age, sex, height and race
to determine the predicted values. The study partici-
pants were classified, using the pre- and post-bronchodi-
lator lung function, into five lung function categories
based on a modification of COPD classification criteria:
Normal (no airflow obstruction or restriction), restricted
(FEV1/FVC ≥ 70% and FVC < 80% of predicted), Stage 1
(FEV1/FVC < 70% and FEV1 ≥ 80% predicted), Stage 2
(FEV1/FVC < 70% and 50% ≤ FEV1 <8 0 %p r e d i c t e d ) ,
and Stage 3 or 4 (FEV1/FVC < 70% and FEV1 < 50%
predicted) [4].
Definitions
D e m o g r a p h i cd a t ai n c l u d e di nt h i sa n a l y s i sw e r es e x ,
age, body mass index (BMI), smoking status, race, and
educational status. Age was classified at baseline, the
year 1, and year 5 examinations and was categorized for
use in tables (35-39, 40-49, 50-50, and 60 and older),
and was used as a continuous variable in the survival
analyses. BMI was categorized at baseline and was cate-
gorized into 3 categories (< 25, 25-29, and > = 30 kg/
m
2), and was used as a continuous variable in the survi-
val analyses. All subjects were smokers at baseline, so
smoking status was classified based on their second
through fifth follow-up visits as current smokers for
those who never stopped smoking, former smokers for
those who successfully quit, and intermittent smokers
for those whose status varied [20]. Education status was
stratified into three levels (< 12 years, 12 years, and > 12
years). Race was classified as White or Black, with peo-
ple of other races excluded. The original design of the
study was incorporated by stratifying the subjects by
randomization group: Intervention with ipratroprium,
Intervention with placebo, and Control.
Statistical Analysis
Data analysis was completed using statistical software
(Statistical Analysis Software, version 9.2; SAS Institute;
Cary, NC and SUDAAN version 10.1; RTI, Research
Triangle Park, NC). Our primary outcome of interest in
the survival models was mortality, and the main predic-
tor of interest in our analysis was COPD severity
defined by stage of lung function, both pre- and post-
bronchodilator, and a separate analysis using FEV1 as a
percent of predicted, both pre- and post-bronchodilator.
We calculated the deaths per 1,000 person years of fol-
low-up for our key covariates. Cox proportional hazard
regression models were developed using the SUDAAN
procedure SURVIVAL to account for differential follow
up in cohort participants. Time of follow up was used
as the underlying time metric. Censoring occurred at
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last known to be alive. Plots of the log-log survival
curves for each covariate were produced to evaluate the
proportional hazards assumptions. Age, sex, race, smok-
ing status, education level, body mass index and rando-
mization cohort were included in the adjusted models.
Results
There were a total of 5,887 participants in the Lung
Health Study, of whom 721 died by the end of the fol-
low-up period of up to 15 years. The major causes of
death at follow-up were lung cancer and cardiovascular
disease with comparatively fewer deaths due to non-
malignant respiratory disease. At baseline, the mean age
of the cohort was 48.5 years and the mean FEV1 was
74.7%. Of these, we had complete data on 5,307 who
participated in the examination at year 1 (there were 13
deaths before the year 1 visit). Among the 5,307 on
whom we had complete data at year 1, we had 65,472
person years of follow-up, with a median and maximum
follow-up time of 12.8 and 14.0 years, and 628 deaths
(Table 1). Among the 5,320 on whom we had complete
data at year 5 (there were 149 deaths prior to the year 5
visit), we had 45,808 person years of follow-up, with a
median and maximum follow-up time of 8.8 and 10.0
years, and 500 deaths (Table 2).
Table 1 provides additional detail on the covariates of
the cohort at year 1, including the total follow-up time
and the mortality rate per 1,000 person-years of follow-
up. As would be expected, age was the strongest predic-
tor of mortality. Similar da t af o rt h eY e a r5c o h o r ti s
displayed in Table 2.
Changes in the COPD classification stages between
pre- and post-bronchodilator lung function measure-
ments for the year 1 and the year cohort is shown in
T a b l e3 .A ty e a r1 ,3 , 8 0 4o f5 , 3 0 7( 7 1 . 7 % )r e m a i n e di n
the same category for both pre- and post-bronchodilator
FEV1a n da ty e a r5 ,4 , 0 7 9o f5 , 3 2 0( 7 6 . 7 % )r e m a i n e di n
the same category for both pre- and post-bronchodilator
FEV1.T h em e a nF E V 1, as a percentage of predicted,
increased from 74.1% (Standard deviation [SD] 10.3%)
to78.1% (SD 10.0%) at year 1 and from 70.3% (SD
12.5%) to 74.3% (SD 12.1%) at year 5.
The Cox proportional hazards models for the year 1
c o h o r ta r es h o w ni nT a b l e4 .A g e ,s e x ,e d u c a t i o nl e v e l ,
race, and smoking status were significant predictors of
mortality, but in these models COPD classification stage
reached statistical significance in only stage 2 of the
post-bronchodilator model. The area under the curve,
from the PROC logistic model, was 69.2% for the pre-
and 69.6% for the post- bronchodilator model. In paral-
lel models that used pre- and post-bronchodilator FEV1,
a sap e r c e n t a g eo fp r e d i c t e d ,ah i g h e rF E V 1 % predicted
lower mortality in both the pre- (HR 0.87, 95% CI 0.81,
0.94 per 10% increase) and post-bronchodilator (HR
0.84, 95% CI 0.77, 0.90) models. The area under the
curve for the respective models was 69.2% and 69.4%.
Similar models for the year 5 follow-up data are
s h o w ni nT a b l e5 .T h em a i nd i f f e r e n c es e e nb e t w e e n
the year 1 and year 5 models is that the latter now show
an increased risk of Stage 3 or 4 COPD on mortality in
both the pre- (HR 2.68, 95% CI 1.51, 4.75) and post-
bronchodilator (HR 2.46, 95% CI 1.63, 3.73) models.
T h ea r e au n d e rt h ec u r v ew a s6 9 . 0 %f o rt h ep r e -a n d
69.5% for the post-bronchodilator models. Similar mod-
els using FEV1 showed that a higher FEV1 % predicted
lower mortality in both the pre-bronchodilator (HR
0.84, 95% CI 0.75, 0.87 per 10% increase) and post-
bronchodilator (HR 0.78, 95% CI 0.73, 0.90) models.
The area under the curve for the respective models was
69.4% and 69.8%.
Discussion
This analysis examined data from the Lung Health
Study to determine whether post-bronchodilator lung
function predicts mortality. Overall, we found that the
pre- and post-bronchodilator measures of lung function,
whether used categorically (as stages of COPD) or con-
tinuously (as FEV1 % predicted) predicted mortality
similarly. This finding suggests that post-bronchodilator
lung function data may not be needed for studies that
look at long term outcomes in COPD.
Most guidelines defining COPD say that spirometry
should be performed after the administration of an ade-
quate dose of an inhaled bronchodilator in order to
minimize variability [4,21]. These same guidelines, how-
ever, state that “neither bronchodilator nor oral gluco-
corticosteroid reversibility testing predicts disease
progression, whether judged by decline in FEV1, dete-
rioration of health status, or frequency of exacerbations
in patients with a clinical diagnosis of COPD and abnor-
mal spirometry. Small changes in FEV1 (e.g., < 400 ml)
after administration of a bronchodilator do not reliably
predict the patient’s response to treatment" [4]. Others
have suggested that one cannot use prebronchodilator
lung function to define COPD, the reason being that
airflow limitation can be variable and that this compo-
nent can be easily reverse with a bronchodilator [22].
Other research, though, has suggested that bronchodila-
tor responsiveness is highly variable and that “over half
the patients initially classified as reversible by the ATS/
GOLD definition would be reclassified had they
attended on another occasion” [23].
In population-based studies, one would expect that
post-bronchodilator lung function measurement would
reduce the prevalence of COPD. For example, in the
PLATINO study, bronchodilator testing reduced the
overall prevalence of FEV1/FVC% < 0.70 from 21.7% to
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was lower in the post- compared to the pre-bronchodi-
lator lung function in both the year 1 (0.4% vs. 1.3%)
and the year 5 (3.4% vs. 6.4%) cohorts. The finding of a
lower prevalence, however, does not necessarily mean
that this is the correct prevalence.
Table 1 Characteristics of Analyzed Population at Year 1
(n = 5,307) with 628 deaths at up to 15 years of follow-
up
N % Person-Years of
Follow-up
Deaths per 1,000
Person Years
Sex
Female 1993 37.6 24,764 8.3
Male 3314 62.4 40,708 10.4
Age Group, Years
35-39 522 9.8 6,610 3.8
40-49 2099 39.6 26,350 5.5
50-59 2494 47.0 30,267 13.7
60+ 192 3.6 2,245 18.7
Body Mass Index,
kg/m
2
< 25 2528 47.6 31,168 9.5
25- 30 2082 39.2 25,791 9.1
> = 30 697 13.1 8,513 11.5
Education, Years
< 12 632 11.9 7,720 13.0
12 1592 30.0 19,629 10.0
> 12 3083 58.1 38,123 8.7
Race
White 5108 96.3 63,117 9.2
Black 199 3.7 2,355 20.8
Smoking Status
Former 1439 27.1 17,966 7.0
Intermittent 628 11.8 7,752 9.5
Current 3240 61.1 39,754 10.8
Randomization
Group
Intervention,
Ipratroprium
1793 33.8 22,141 8.9
Intervention,
Placebo
1785 33.6 22,108 9.0
Control 1729 32.6 21,223 11.0
Stage (pre-
bronchodilator)*
Stage 3 or 4 67 1.3 799 15.0
Stage 2 3432 64.7 42,208 10.7
Stage 1 1354 25.5 16,852 7.3
Restricted 69 1.3 840 9.5
Normal 385 7.3 4,773 6.7
Stage (post-
bronchodilator)*
Stage 3 or 4 19 0.4 224 13.4
Stage 2 2540 47.9 31,126 12.1
Stage 1 1565 29.5 19,386 7.8
Restricted 125 2.4 1,487 12.1
Normal 1058 19.9 13,249 5.8
*Modified chronic obstructive pulmonary disease stage, as defined in methods
Table 2 Characteristics of Analyzed Population at Year 5
(n = 5,320) with 500 deaths at up to 10 years of follow-
up
N % Person-Years
of Follow-up
Deaths per 1,000
Person Years
Sex
Female 1,992 37.4 17,221 9.4
Male 3,328 62.6 28,587 11.8
Age Group, years
35-39 25 0.5 214 9.3
40-49 1,708 32.1 14,995 4.7
50-59 2,436 45.8 20,954 11.4
60+ 1,151 21.6 9,644 19.7
Body Mass Index, kg/
m2
< 25 2,536 47.7 21,849 10.7
25- 30 2,098 39.4 18,075 10.6
> = 30 686 12.9 5,884 12.7
Education (years)
< 12 639 12.0 5,496 14.0
12 1,595 30.0 13,735 11.5
> 12 3,086 58.0 26,577 10.0
Race
White 5,136 96.5 44,226 10.6
Non-White 184 3.5 1,582 19.6
Smoking Status
Former 1,386 26.1 12,063 7.5
Intermittent 627 11.8 5,403 10.2
Current 3,307 62.2 28,342 12.5
Randomization Group
Intervention,
Ipratroprium
1,791 33.7 15,470 9.6
Intervention,
Placebo
1,770 33.3 15,271 10.5
Control 1,759 33.1 15,067 12.7
Stage (pre-
bronchodilator)*
Stage 3 or 4 341 6.4 2,831 21.5
Stage 2 3,587 67.4 30,875 11.3
Stage 1 995 18.7 8,674 7.3
Restricted 92 1.7 768 15.6
Normal 305 5.7 2,659 5.6
Stage (post-
bronchodilator)*
Stage 3 or 4 183 3.4 1,475 29.8
Stage 2 3,048 57.3 26,237 12.0
Stage 1 1,242 23.3 10,775 7.2
Restricted 126 2.4 1,059 13.2
Normal 721 13.6 6,262 7.8
*Modified chronic obstructive pulmonary disease stage, as defined in methods
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For example, Hansen et al studied 985 patients with
COPD and found that the response to a bronchodilator
was a positive prognostic factor along with FEV1 at base-
line. However, if baseline FEV1 was substituted with post-
bronchodilator FEV1, the bronchodilator reversibility
became nonsignificant [25]. Compared to our population,
that population had much lower lung function (mean
FEV1 38.5% of predicted compared to our mean FEV1 of
74.7%) and was much older (mean age 61.8 years at base-
line compared to our mean age of 48.5 years). Still, the
predictive value for FEV1 in their study was similar in the
pre- (relative risk [RR] 0.60, 95% CI 0.54, 0.81) and post-
bronchodilator (RR 0.62, 95% CI 0.56, 0.69) models.
Burrows acknowledged the complexity of the relation
between bronchodilator responsiveness and outcomes in
obstructive lung disease [26]. He noted that different
studies had varying results [27,28] and suggested that
several factors, such as how baseline lung function is
determined, how responsiveness is measured, and the
prevalence of “asthma” in the studied population, may
be important determinants of outcomes. His conclusion
that mortality is “related to age and to a low initial post-
bronchodilator FEV1“ provides, in part, the historic
rationale for using post-bronchodilator lung function to
define COPD.
This study has limitations that are important to its
interpretation. The most important was that it was not
at r u e“population-based” study but was a clinical
intervention trial that targeted early COPD. Study par-
ticipants had to be current smokers at entry with lung
function that was mildly abnormal, and subjects who
regularly used bronchodilators were excluded.
Although asthma history was not a specific exclusion
criterion, excluding people with regular bronchodilator
use had the net effect of eliminating subjects with
clinically significant asthma from the population. Thus,
these findings may not necessarily apply to a popula-
tion that includes never smokers or where a large pro-
portion of the population has asthma that is
symptomatic. Also, a more inclusive population of
smokers where reversibility is more common may have
yielded different results. This limitation is decreased by
our study design that looked at data from the year 1
a n dy e a r5f o l l o w - u p ,a tw h i c hp o i n ts o m es u b j e c t s
had stopped smoking and many developed symptoms
consistent with asthma or COPD. In addition, one
would not expect the post-bronchodilator FEV1 of
never smokers (in the absence of asthma) to differ sig-
nificantly from the pre-bronchodilator value. Finally,
the dose of bronchodilator used in this study (two
inhalations, 200-μg total dose, of isoproterenol) is less
than what has been used in other clinical trials, some
of which have used 400 μg of isoproterenol and 400 μg
of albuterol [29]. Thus, it is unknown whether the
findings would be similar if a “maximal bronchodilita-
tion” protocol was used.
Another limitation was the absence of other important
measures of COPD, such as an impaired exercise test-
ing, impaired diffusion capacity or abnormal imaging.
Recent work [30-32] in COPD has highlighted that mea-
sures other than lung function are important predictors
of impaired function and poor outcomes. Lung function
remains, however, the primary means of diagnosing and
Table 3 Comparison of pre- and post-bronchodilator classifications from Year 1 and Year 5 visits
Year 1 Post-Bronchodilator
Pre-Bronchodilator Stage 3 or 4* Stage 2 Stage 1 Restricted Normal Total
Stage 3 or 4* 17 50 0 0 0 67
Stage 2 1 2442 578 76 335 3432
Stage 1 0 28 959 0 367 1354
Restricted 1 10 0 44 14 69
Normal 0 10 28 5 342 385
Total 19 2540 1565 125 1058 5307
Year 5
Post-Bronchodilator
Pre-Bronchodilator Stage 3 or 4* Stage 2 Stage 1 Restricted Normal Total
Stage 3 or 4* 172 168 0 1 0 341
Stage 2 10 2823 482 67 205 3587
Stage 1 0 27 748 0 220 995
Restricted 1 18 1 56 16 92
Normal 0 12 11 2 280 305
Total 183 3048 1242 126 721 5320
The rows represent the pre-bronchodilator values and the columns represent the post-bronchodilator values (i.e. at year one 67/5307 were stage 3 or 4 pre- and
19/5307 were stage 3 or 4 post-bronchodilator). Year 1 Post-Bronchodilator
*Modified chronic obstructive pulmonary disease stage, as defined in methods
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to change in the foreseeable future.
Conclusion
We found that is this cohort both pre- and post-bronch-
odilator lung function predicted mortality with similar
accuracy. This validates the approach taken in a number
of long-term studies where only prebronchodilator lung
function is available, although studies that include simi-
lar data in never smokers and subjects with asthma are
needed.
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Table 4 Results from Cox Proportional hazards survival
models on year 1 sample- Mortality follow-up of up to
15 years
Hazards
Ratio
95% Confidence
Interval
Sex
Male 1.34 (1.12, 1.59)
Female 1.00
Age 1.09 (1.07, 1.10)
Body Mass Index 1.00 (0.98, 1.03)
Education
< 12 Years 1.29 (1.03, 1.61)
12 Years 1.08 (0.90, 1.29)
> 12 Years 1.00
Race
White 1.00
Black 2.13 (1.57, 2.88)
Smoking Status
Former Smoker 0.64 (0.52, 0.79)
Intermittent Smoker 0.89 (0.69, 1.15)
Current Smoker 1.00
Randomization Group
Intervention,
Ipratroprium
0.92 (0.76, 1.12)
Intervention, Placebo 0.89 (0.74, 1.09)
Control 1.00
Stage (Pre-bronchodilator)*
Stage 3 or 4 1.51 (0.75, 3.03)
Stage 2 1.36 (0.95, 1.95)
Stage 1 0.97 (0.65, 1.44)
Restricted 1.12 (0.51, 2.48)
Normal 1.00
Stage (Post-bronchodilator)*
Stage 3 or 4 1.45 (0.41, 5.15)
Stage 2 1.54 (1.20, 1.98)
Stage 1 1.06 (0.80, 1.40)
Restricted 1.63 (0.96, 2.75)
Normal 1.00
Results for post-bronchodilator lung function measurement is displayed
without showing results for the other covariates.
*Modified chronic obstructive pulmonary disease stage, as defined in methods
Table 5 Results from Year 5 sample, mortality follow-up
of up to 10 years
Hazards
Ratio
95% Confidence
Interval
Sex
Male 1.36 (1.12, 1.64)
Female 1.00
Age 1.09 (1.07, 1.10)
Body Mass Index 1.01 (0.98, 1.03)
Education
< 12 Years 1.24 (0.96, 1.59)
12 Years 1.10 (0.90, 1.34)
> 12 Years 1.00
Race
White 1.00
Black 1.77 (1.22, 2.56)
Smoking Status
Former Smoker 0.63 (0.50, 0.80)
Intermittent Smoker 0.85 (0.64, 1.13)
Current Smoker 1.00
Randomization Group
Intervention,
Ipratroprium
0.86 (0.69, 1.07)
Intervention, Placebo 0.91 (0.74, 1.13)
Control 1.00
Stage (Pre-bronchodilator)*
Stage 3 or 4 2.68 (1.51, 4.75)
Stage 2 1.60 (0.94, 2.69)
Stage 1 1.12 (0.63, 1.98)
Restricted 2.25 (1.04, 4.86)
Normal 1.00
Stage (Post-bronchodilator)*
Stage 3 or 4 2.46 (1.63, 3.73)
Stage 2 1.11 (0.82, 1.51)
Stage 1 0.74 (0.52, 1.06)
Restricted 1.36 (0.74, 2.47)
Normal 1.00
*Modified chronic obstructive pulmonary disease stage, as defined in methods
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